Related Experiment Video
Updated: Aug 17, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
[Immunotherapy of superficial bladder cancer]
B J Schmitz-Dräger1, S O Schattka, T Ebert
1Urologische Klinik, Heinrich-Heine-Universität, Düsseldorf.
Abstract:
Because patients with superficial bladder cancer are in a high-risk group where tumor progression is concerned, topical therapeutic strategies are necessary to prevent tumor recurrence and tumor progression. Based on experimental studies and several case reports, during the last two decades immunotherapy for superficial bladder cancer has been developed. The effects of topical instillation of bacillus Calmette-Guerin (BCG) has been carefully investigated in numerous clinical trials. Especially patients with carcinoma in situ appear to benefit from BCG therapy. Other types of local immunotherapy, e.g., instillation of interferons, interleukins, and keyhole limpet hemocyanin have been found to have fewer side effects than BDG. These new approaches are currently under clinical investigation.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

